prostate cancer

Uro Pipeline: Trial launched for drugs' use in metastatic, hormone-sensitive PCaA novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.
Markers redefining prostate cancer careIn this interview, Daniel W. Lin, MD, discusses the practical use of currently available molecular and genomic tests, cost and reimbursement considerations, the role of MRI, and what the future holds for biomarkers.
Pre-op mpMRI variables predict post-RARP recurrenceFindings from preoperative multiparametric magnetic resonance imaging may enhance risk stratification, surgical planning, and patient counseling for men with prostate cancer, according to researchers from the National Institutes of Health, Bethesda, MD.
C-11 choline PET, pMRI identify recurrence patternsC-11 choline positron emission tomography and multiparametric pelvic magnetic resonance imaging (pMRI) can be used successfully to identify recurrence patterns in patients with biochemical recurrence after radical prostatectomy.
Concomitant Ra 223, abiraterone found safe, effectiveRadium 223 dichloride (Ra 223 [Xofigo]) can be safely combined with abiraterone acetate (ZYTIGA) for the treatment of patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases, and appears to result in decreased bone pain and improved quality of life, according to the interim results of an open-label prospective study known as eRADicAte.
Placement of a hydrogel rectal spacer before RT for prostate Ca
Placement of a hydrogel rectal spacer before RT for prostate CaMany approaches have been tried for reducing the rectal toxicity of radiotherapy (Radiat Oncol 2013; 8:96; Int J Radiat Oncol Biol Phys 2012; 82:1918-22; Radiat Oncol 2014; 9:96). This article discusses a newer therapy that involves the injection of a temporary hydrogel in the plane between the prostate and rectum.
Uro Pipeline: FDA grants priority review to advanced bladder Ca agentAlso look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.
Data support PCa markers, but more study neededA leader in urologic oncology discusses four currently available molecular tests in this report from Urology Times SUO internship program member Brandon Manley, MD.
PCa: How positive family history predicts outcomesUrology Times SUO internship program member Cory Hugen, MD, reports on a recent Mayo Clinic study on familial history’s impact on post-RP outcomes and survival.
Radiation center volume linked to prostate Ca outcomesIn a recently published study, researchers analyzed data from nearly 20,000 high-risk prostate cancer patients at more than 1,000 facilities.